Stem Cell Transplantation Clinical Trial
Official title:
Does Myeloid or Lymphoid Origin of Hematologic Neoplasm Affect Pulmonary Functions, Muscle Strength, Exercise Capacity, Fatigue and Quality of Life?
Hematologic malignancies may arise from myeloid and lymphoid blood cells lineages affecting blood, bone marrow and lymph nodes. Accordingly, negative effects of malignancies on body systems vary. As known, muscle strength, exercise capacity, fatigue and quality of life deteriorate during allogeneic hematopoietic stem cell transplantation (HSCT). However, impacts of myeloid and lymphoid type disorders on pulmonary functions, muscle strength, exercise capacity, fatigue and quality of life in allogeneic-HSCT who diagnosed with hematologic malignancies. Therefore, current study aimed to comparatively investigate physical impairments between recipients with hematologic malignancies according to myeloid and lymphoid type disorder.
Hematologic malignancies affecting blood, bone marrow and lymph nodes comprise neoplasm of
either myeloid or lymphoid blood stem cells origin. While a lymphoid stem cell becomes a
white blood cell, a myeloid stem cell becomes one of the red blood cells, white blood cells
or platelets types. Due to the this reason, defects in myeloid stem cells result in acute and
chronic myelogenous leukemia, myelodysplastic syndromes or myeloproliferative diseases,
whereas defects in lymphoid stem cells result in lymphomas, lymphocytic leukemias or myeloma.
On the other hand, most of these hematologic malignancies are characterized with high rate of
morbidity and mortality because of both the nature and various toxic treatments of neoplasm
including chemotherapy with multiple agents, corticosteroids and hematopoietic stem cell
transplantation (HSCT). Especially after allogeneic-HSCT, recipients experience more
impairments in pulmonary functions, respiratory and peripheral muscle strength, exercise
capacity, perception of fatigue and quality of life scores which make their lives difficult
in terms of actively trying to return to the their life. However, although it has been known
that each hematologic disease has a different negative impact on varied body systems or
organs after HSCT, little attention has been paid to the comparatively investigation of
impacts of myeloid and lymphoid hematological malignancies on pulmonary functions, muscle
strength, exercise capacity, fatigue and quality of life in allogeneic-HSCT recipients.
Hence, current study aimed to comparatively investigate physical impairments between
recipients with hematologic malignancies according to myeloid and lymphoid type disorder.
Recipients undergone allogeneic-HSCT (˃100 days post-HSCT status) were included. Hematologic
malignancies were grouped as myeloid and lymphoid. Pulmonary functions (spirometry),
peripheral (dynamometer) and respiratory muscle strength (MIP-MEP) (mouth pressure device),
exercise capacity (Modified Incremental Shuttle Walk Test (ISWT)), and quality of life
(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire)
were evaluated.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03918343 -
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
|
N/A | |
Not yet recruiting |
NCT05438823 -
Technology Supported Education Program Based on Human Care Theory
|
N/A | |
Not yet recruiting |
NCT02193399 -
Physiotherapy in Hematopoietic Stem Cell Transplantation
|
N/A | |
Withdrawn |
NCT00972101 -
Infusion of Expanded Cord Blood T Cells
|
Phase 1 | |
Completed |
NCT05421299 -
A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate
|
||
Completed |
NCT04976933 -
Post-HSCT Medication Adherence mHealth App
|
||
Completed |
NCT04798495 -
Feasibility of a Rehabilitation Programme Targeted Patients Treated With Non-myeloablative Stem Cell Transplantation
|
N/A | |
Completed |
NCT00612274 -
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
|
Phase 0 | |
Active, not recruiting |
NCT04511130 -
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT05968963 -
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT02940093 -
Pipeline Integrating Gut Metagenome Data, Host Immunogenetic Characteristics and Clinical Gut Inflammatory Biomarkers
|
N/A | |
Not yet recruiting |
NCT06077734 -
Muscle Stem Cell Quality in Atrophy
|
||
Terminated |
NCT00587990 -
Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)
|
Phase 1/Phase 2 | |
Terminated |
NCT00597441 -
Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation
|
Phase 1 | |
Active, not recruiting |
NCT03684083 -
Inflammatory Response to Paramyxovirus Infection in an Ex-vivo Model of Bronchial Epithelial Cells in Allogeneic HSCT Recipients
|
||
Recruiting |
NCT00884338 -
Cognitive Function After Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT00284713 -
Progenitor Cell Therapy in Dilative Cardiomyopathy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00062543 -
Hepatic Artery Infusion of CD34+ Cells
|
Phase 1 | |
Completed |
NCT00781170 -
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT03364257 -
iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patients
|